Riskpilot← Back to searchSign inGet full accessMOLOKLINIKKEN AS
ASActiveOrg 914480752V/ Akerkvartalet Oksenøyveien 10, 1366 LysakerMedical specialists activities · NACE 8622Est. 201439 employeeswww.moloklinikken.no
Revenue 2025
NOK 109,9M
+23% vs 2024
EBITDA margin
17.1%
+56% vs 2024
Equity ratio
14.4%
Financial strength
Net profit 2025
NOK 14,8M
+69% vs 2024
| Revenue | NOK 109,9M | +23% |
| EBITDA | NOK 18,8M | +56% |
| Net profit | NOK 14,8M | +69% |
| Total assets | NOK 81,4M | +87% |
| Equity | NOK 11,8M | +1006% |
| Employees | 39 | — |
Legal name
MOLOKLINIKKEN AS
Org number
914480752
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
17. november 2014
Share capital
NOK 1 000 000
Employees
39 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Daglig leder alene.
Company purpose
Selskapets virksomhet består i å levere og utvikle helsetjenester innen allmenn- og spesialisttjenesten, fasilitere helsetjenester, utleie av helsepersonell samt delta og/eller investere i selskaper med lignende formål.
Address
V/ Akerkvartalet Oksenøyveien 10, 1366 Lysaker
Phone
+4767222870
Email
post@moloklinikken.no
Website
www.moloklinikken.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 2 509 | 11 498 | 15 670 | 19 108 | 28 140 | 29 155 | 30 038 | 33 244 | 66 123 | 89 252 | 109 936 |
| Staff expenses | −0 | −1 209 | −4 742 | −5 674 | −7 550 | −9 684 | −9 882 | −13 170 | −16 293 | −24 086 | −34 199 | −40 977 |
| EBITDA | 0 | −942 | −1 528 | −233 | 2 138 | 4 527 | 2 752 | 2 070 | 2 598 | 7 326 | 12 027 | 18 821 |
| Depreciation & amort. | −0 | −173 | −996 | −1 089 | −1 195 | −1 199 | −1 303 | −1 465 | −1 465 | −1 320 | −2 079 | −2 282 |
| EBIT | 0 | −1 115 | −2 524 | −1 322 | 943 | 3 328 | 1 449 | 604 | 1 133 | 6 006 | 9 948 | 16 539 |
| Net financials | 0 | −88 | −198 | −211 | −262 | −258 | −129 | −46 | 100 | 708 | 1 247 | 2 147 |
| Profit before tax | 0 | −1 203 | −2 722 | −1 533 | 681 | 3 070 | 1 320 | 559 | 1 233 | 6 714 | 11 195 | 18 686 |
| Tax | 0 | −301 | −641 | −313 | 204 | 676 | 43 | 125 | 272 | 1 480 | 2 466 | 3 916 |
| Net profit | 0 | −902 | −2 081 | −1 220 | 476 | 2 394 | 1 277 | 433 | 961 | 5 234 | 8 730 | 14 770 |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 30 | 6 963 | 8 948 | 9 833 | 10 842 | 13 830 | 10 927 | 14 696 | 23 591 | 44 071 | 43 662 | 81 439 |
| Equity | 30 | −872 | 1 017 | −203 | 273 | 2 668 | 2 819 | 3 253 | 4 033 | 1 047 | 1 063 | 11 753 |
| Long-term debt | 0 | 4 942 | 5 838 | 6 831 | 7 037 | 5 825 | 499 | 441 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 2 894 | 2 093 | 3 205 | 3 531 | 5 337 | 7 609 | 11 002 | 19 558 | 43 024 | 42 599 | 69 686 |
| Total debt | 0 | 7 836 | 7 931 | 10 036 | 10 569 | 11 162 | 8 108 | 11 444 | 19 558 | 43 024 | 42 599 | 69 686 |
EBITDA margin
17.1%
This company
15.8%
Market median
+8% vs market
20142025
Equity ratio
14.4%
This company
38.2%
Market median
-62% vs market
20142025
Return on equity
125.7%
This company
18.4%
Market median
+583% vs market
20142025
Net profit margin
13.4%
This company
8.1%
Market median
+65% vs market
20142025
Asset turnover
1.35×
This company
1.12×
Market median
+21% vs market
20142025
Debt / equity
5.93×
This company
0.62×
Market median
-856% vs market
20142025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-11-11 – 2014-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JH Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2016 | — | — | |
| Chairman | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Condor Holding As | Company | 90.1% | 90.1% | 2024 |
Aker Capital As | Company | 9.9% | 9.9% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Trg Holding As
MOLOKLINIKKEN AS Board members of MOLOKLINIKKEN AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| John Helge Haugnæss | Chief Executive Officer | 0 companies |
| Even Holt | Board of Directors | 0 companies |
| Håvard Andresen | Board of Directors | 0 companies |
| Anne Grete Eidsvig | Board of Directors | 0 companies |
| Øyvind Eriksen | Chairman | 0 companies |